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ARTICLE
Dynamic consent: a patient interface for twenty-first
century research networks
Jane Kaye*,1, Edgar A Whitley2, David Lund3, Michael Morrison1, Harriet Teare1 and Karen Melham1
Biomedical research is being transformed through the application of information technologies that allow ever greater amounts
of data to be shared on an unprecedented scale. However, the methods for involving participants have not kept pace with
changes in research capability. In an era when information is shared digitally at the global level, mechanisms of informed
consent remain static, paper-based and organised around national boundaries and legal frameworks. Dynamic consent (DC) is
both a specific project and a wider concept that offers a new approach to consent; one designed to meet the needs of the
twenty-first century research landscape. At the heart of DC is a personalised, digital communication interface that connects
researchers and participants, placing participants at the heart of decision making. The interface facilitates two-way
communication to stimulate a more engaged, informed and scientifically literate participant population where individuals can
tailor and manage their own consent preferences. The technical architecture of DC includes components that can securely
encrypt sensitive data and allow participant consent preferences to travel with their data and samples when they are shared
with third parties. In addition to improving transparency and public trust, this system benefits researchers by streamlining
recruitment and enabling more efficient participant recontact. DC has mainly been developed in biobanking contexts, but it
also has potential application in other domains for a variety of purposes.
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INTRODUCTION
The twenty-first century has been marked by considerable innovation in
the field of information technology (IT), which has led to rapid changes
in the way that biomedical research is carried out.1 Biomedical research
is now heavily dependent upon infrastructures such as biobanks and
data repositories and is ‘increasingly of a global nature with data and
samples exchanged, accumulated and created through a number of
dynamic research networks and consortia that involve multi-disciplinary
teams located in different countries’.2 This new way of doing research
has been accompanied by the development of new ethical norms,
practices and standards particularly in the area of consent.3 Despite
innovations in the use of technology to develop research capabilities, the
potential to use technology to address some of the ethical and legal
issues around research participation has not been fully realised.4
This paper describes the dynamic consent model, which is an example
of how IT can be used to satisfy the legal and regulatory requirements
for research consent, while at the same time providing a personalised
communication interface for interacting with patients, participants and
citizens. It was initially developed in the field of biobanking but has the
potential to be applied more broadly to situations where there are
multiple and varied uses of data requiring different kinds of consent over
a long period of time. Therefore, ‘dynamic consent’ refers to a specific
project in the field of biobanking but is also a more general concept and
approach that has the potential to radically change the nature of
participation in both clinical care and research.
THE CHALLENGE OF CONSENT
The requirement that researchers obtain informed consent from
potential participants before research commences is a fundamental
principle of medical research, enshrined in the Declaration of Helsinki
and subsequent legal instruments.5,6 The requirement for consent is
underpinned by ethical principles of respect for persons and
individual autonomy. Consent is also the basis for data protection
and privacy law in most countries although there may be exceptions
for medical research.7
The consent form has become the primary means of recording
individual involvement in research, and for determining ‘whether
additional consent is required, or whether the existing consent covers
the new research’.8 As such, it formalises part of the implicit social
contract between the public and researchers. New forms of biomedical
research and the ease by which multiple data from diverse sources can
now be collected, stored, analysed and shared in greater volumes than
ever before9–11 challenge the meaning of informed consent and call
into question whether the existing processes of engaging with
participants are still appropriate for these new dynamic ways of
undertaking research.
In the case of biobanks where there are multiple researchers and
research projects, it is difficult to obtain informed consent for all future
research uses at the time of recruitment into the biobank or before such
research commences, as is required in the original formulations of the
Declaration of Helsinki.12 Re-consenting is costly and time-consuming,
and difficulty in locating people can result in high drop-out rates. As a
practical solution, broad consent is often obtained with participants
agreeing to the ‘rules of the game’; that the material may be shared
widely and used by many researchers.3,13,14 There are a number of
reasons, however, why this approach is inadequate to meet the
demands of meaningfully informed consent. Unlike traditional
research, there is no single ‘experimental procedure’ with fixed
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duration, end points or outputs, in which individuals are being asked
to participate. Instead, individuals are being asked to consent to
involvement in ongoing research infrastructures with multiple,
emergent research questions and methods, where the potential
privacy risks of personal and individually identifying health
information may be a greater concern than the risk of physical
harm.15–17 As the nature of biomedical research changes, the social
contract between participants and researchers needs to evolve with it. If
biobank research is open-ended and ongoing then information
technologies offer the possibility for participant involvement similarly
to extend through time. Individuals need no longer be passive human
‘subjects’ but can be engaged over time and recognised as active,
interested and valued research participants.4,18,19
The expression of individual autonomy is also not static: it involves
making choices and decisions, such as the decision to consent to
participate in research, over the course of one’s lifetime. Indeed, current
guidelines already recognise consent as a process; an ongoing interac-
tion between researcher and participant.20,21 The paper-based tools that
have been used to record consent have, however, limited ongoing
engagement.22 ‘Respect for persons’ means giving individuals as much
choice and control in what is done with their personal information and
material as is reasonably achievable.23 This principle is reflected in
case law; where the courts have found that ‘subject to [certain]
qualifications y an individual’s personal autonomy makes him –
should make him – master of all those facts about his own identity, such
as his name, health, sexuality, ethnicity, his own imagey and also of
the ‘zone of interaction’y between himself and others’.24 This principle
is also evident in the proposed European Data Protection Regulations.25
Many longitudinal biobanks, which inherently involve an ongoing
engagement with participants, have already recognised the limitations
of a one-off static consent and employ ongoing monitoring and
governance mechanisms to enable participant recontact over time.
These mechanisms represent transitional movements along the
continuum from broad to tiered or more flexible forms of consent.
Examples of best practice, such as UK Biobank and the Norwegian
Mother Child Cohort Study, rely on a broad consent but also provide
regular updates to participants on ongoing biobanking activity.26
However, for many biobanks these services are seen as patient
communication ‘extras’, and there is little attention to the
possibilities of information technologies to enable dialogue and
engagement between researchers and participants.
Technological advances are also enabling the collection of richer and
more comprehensive ‘personalised’ data sets. Many of the traditional
protections used in research such as anonymisation, coding and
pseudonymisation are increasingly tested or rendered ineffectual by
advanced data collection.17,27,28 The potential that individuals can be
identified either directly or indirectly from the data may invoke
the requirement for explicit consent under data protection and
privacy law.29 The current proposals for the European Data
Protection Regulations suggest the requirement for medical research
will be explicit consent,25 which brings into question whether broad
consent will remain a lawful option for research.
As informatics technology becomes more powerful and the ability
to link different data sets increases, the static, paper-based systems for
recording consent are no longer fit for purpose. New approaches are
needed to meet ethical and legal requirements for consent and to
accommodate the fluidity of data flows in research networks.
Dynamic consent addresses the changing nature of biomedical
research and allows researchers to overcome the limitations of static
consent, the increasing obsolescence of anonymity and the fluctuating
requirements of the legal and regulatory environment.
WHAT IS DYNAMIC CONSENT?
Box 1 Defining Dynamic Consent
Dynamic Consent is a new approach for engaging individuals about the use of
their personal information. It is also an interactive personalised interface that
allows participants to engage as much or as little as they choose and to alter
their consent choices in real time.
Dynamic consent is a personalised, communication interface to
enable greater participant engagement in clinical and research
activities. It is a participant-centred initiative that places patients
and research participants at the centre of decision making, providing
an interactive IT interface to engage with participants.4 This approach
is ‘dynamic’ because it allows interactions over time; it enables
participants to consent to new projects or to alter their consent
choices in real time as their circumstances change and to have
confidence that these changed choices will take effect.
Rather than being restricted to the opportunity only to give broad
consent to the use of their samples and data, individuals could
provide different types of consent depending upon the kind of study.
These consent preferences travel securely with their samples or data so
that third parties know the scope of the consent that applies. A secure
consent interface allows participants to change their consent prefer-
ences reliably. It also allows them to alter their contact details, receive
information on the use of their samples and data, enrol in new studies
and complete online surveys. This allows them to engage with the
research study in their own time, as much or as little as they choose.
Available preferences can be adapted to suit the capabilities and needs
of institutions, researchers and participants.
Box 2 What makes Dynamic Consent ‘dynamic’?
 It allows the same samples/information to be (re)used with the knowledge
and consent of the individual.
 It enables individuals to give and revoke consent to the use of their samples
and information in response to their changing circumstances.
 It provides a record of all transactions and interactions in one place.
 It allows people to be approached for different kinds of consent or to
obtain their opinions as new research projects are started and new ethical
questions arise.
 Consent preferences can be modified over time.
Different consents
By using a technology-based platform, the consent process is not, as is
often the case with paper-based documentation of consent, locked in
time to the beginning of the research process. Depending upon the
nature of the research enterprise, participants could consent to a
broad range of uses of their samples and data, or opt to be
approached on a case-by-case basis, or set different preferences for
different types of research. These preferences can be ‘opt ins’ or ‘opt
outs’: participants can tailor their profiles to receive no information
for specified periods of time or to give a broad consent if they so wish.
The options offered to participants can be set by the biobank or
researcher according to their requirements.
Reliable storage and enforcement of consent choices is achieved by
electronically and cryptographically ‘wrapping’ the individual’s
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consent preferences with samples/information provided. This is
possible because of machine-readable disclosure policies or ‘sticky
policies’ that attach to data.30 This package of ‘wrapped information’,
which contains specific consent provisions, travels with a participant
or donor’s data and samples as these are shared or accessed
for different purposes. ‘Wrapped Information’ embraces new
homomorphic encryption techniques,31 which allow information to
be processed in its encrypted state, while permitting the results of the
processing to remain encrypted. At a later stage, the encrypted result
of the processing can be decrypted to disclose the result. In this case,
the processing itself never decrypts identifiable information but
is still able to generate analytical results from the encrypted data.
Homomorphic encryption provides new, privacy-enhancing,
technical capabilities allowing the processing of sensitive
information through the dynamic consent interface.
It has been suggested that dynamic consent will necessitate partici-
pants giving consent ‘over and over again’ to each new development in a
biobank, whether serious or trivial, and that this fails to respect the
choice of those who prefer to participate passively and may lead to a
‘consent fatigue’ where participants become disengaged and their consent
rendered less meaningful.26 However, this presents a misleading view of
dynamic consent as positioned in opposition to broad consent. Dynamic
consent is not a replacement for existing models such as broad consent
but rather a facilitation tool to improve how that consent is obtained,
understood and acted upon. The ‘opt in’ and ‘opt out’ approach to
choice means that a participant can still choose to give a broad consent
and not receive updates and so on, but if at some future point they wish
to become more engaged they have the option to do so. Similarly, if a
participant finds that they wish to take a break from interacting with a
biobank, perhaps in response to a worsening of a chronic condition, the
dynamic consent interface allows this option.
Tailored
The dynamic consent interface acts as a personalised communication
interface, a source of information and a platform for modifying consent
preferences.32 All aspects of the interface can be tailored to individuals’
needs. Participants can select how they prefer to be contacted and kept
informed, from traditional paper-based formats such as letters or
newsletters to email, SMS (text message) alerts or via social networking
sites, depending upon the capabilities and resources of the biobank.
They can select how often they wish to be contacted and what types of
information they are primarily interested in receiving. For example,
individuals may opt to receive updates on what their biobank is doing,
what new studies are seeking participants or other kinds of feedback
and information. Using a technology platform also allows individuals
to keep track of all of their activities within one accessible interface.
This can be accessed at any time, outside of the clinical or research
setting and without the burden of storing and having to navigate a
potentially substantial archive of paper documents.
A recurring problem for most, if not all, IT-based innovation in the
biomedical context is the so-called ‘digital divide’.33 Access to the
internet is not equally distributed throughout (or between) populations
and is influenced by a range of factors, including age, socio-economic
status and health. Online services run the risk of excluding individuals
and communities with limited or no internet access. Although dynamic
consent cannot claim to provide a solution to all the problems of the
digital divide, there are ways in which it can be tailored to increase
inclusiveness. The dynamic consent interface can run on tablet
computers, websites and also has the potential to be configured for
mobile phones in order to address differing usage needs and preferences
of participants. Mobile or ‘m-health’ options have significant potential
to reach vulnerable or elderly adults and facilitate access to health
information in developing countries where mobile coverage is far more
widespread than other forms of digital infrastructure.34 Further, a
dynamic consent interface can be installed on a device that is delegated
for use by a carer or family member or that can be utilised in the clinic
with a health professional on hand to provide assistance.35 It also should
be run alongside more traditional face-to-face interactions with patients.
Customised to research needs
Dynamic consent explicitly incorporates a flexible, configurable
design accommodating both participant and researcher needs. Bio-
banks, cohorts, clinical trials and consortia have different interactions
with individuals and need to be able to tailor the available consent,
information and communication settings accordingly. Each instantia-
tion of the system can be tailored to meet the needs of each particular
research enterprise, ensuring that settings are appropriate and fit for
purpose to suit both the research and the study population.
This flexibility also extends to the interaction with existing biobank
infrastructures; dynamic consent technology can be configured to work
with a wide range of Laboratory Information Management Systems
and other data storage architectures. Biobanks will not need to replace
existing data management and storage infrastructure to implement a
dynamic consent system. There will, of course, be costs associated with
implementing dynamic consent. These include financial costs of
acquiring and installing the technology as well as work associated
with understanding, specifying and implementing specific consent
options for research settings. It takes time and effort for biobank staff
and participants to learn how to use the interface, and the interface
needs to be populated with relevant and appropriately tailored content,
for example, links to podcasts and online information resources.
However, these costs can be offset in the long term as dynamic consent
is not simply a system for improving consent; it also tracks and stores
participant information (including preferences), facilitates engagement
and provides a range of additional benefits as set out in subsequent
sections of this paper. As the practical implementation of dynamic
consent systems progresses, more information will become available on
the specific costs and optimal approaches for installation, which will
enable detailed cost-benefit analyses.
Box 3 Features of Dynamic Consent
Participants can:
 Consent to new projects with ease or alter their consent preferences in real
time as their circumstances change.
 Change contact information and personal preferences and find out how their
samples have been used via a secure, password-protected section of the
interface.
 Set preferences about the kind of information they receive, how often they
receive it and in what format (eg, text messages, emails, letters).
Researchers can:
 Customise the interface to meet the needs, resources and capabilities of the
research enterprise.
 Integrate the stand-alone online communication interface with other
information systems.
BENEFITS OF DYNAMIC CONSENT
By understanding and supporting biomedical research as a partnership
between participants and researchers, dynamic consent makes possible
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better research and a better research experience for both parties.
The interface offers participants a responsive format through which to
become involved with research; one which respects their autonomy by
enabling information and consent preferences to be exercised and
ultimately providing more meaningful consent. This in turn benefits
researchers by facilitating more engaged participant populations,
streamlining recruitment and improving public trust.36 Easy
configurability allows future possibilities for integrating research and
clinical care, facilitating translational research and improving health-care
outcomes and reducing the costs of research in the long term.
Streamlines recruitment
The costs of recruitment into research are high, and recruitment rates
into publicly funded studies are relatively low. Patients are, however,
very willing to participate in research. In a recent study of 203 adult
patients, 69% wanted to take part in biobank studies.37 The primary
benefit of the dynamic consent model for researchers is that it
simplifies and streamlines consent and recruitment processes. For
each new research request, the dynamic consent software can
automatically select participants who are willing to be involved. Its
interactive functionality provides an easy mechanism for individuals
to be identified, approached and recruited for new studies, to
participate in online surveys or to canvas opinions on a range of
concerns. This makes recruitment less costly, reducing paperwork and
staff time. People are willing to be engaged in research, but current
recruitment processes are not effective. An on-going interaction and
communication capability has the potential to address this imbalance.
Enables efficient recontact
Maintaining contact with participants helps researchers to deal with
many of the ethical and legal problems that emerge from unforeseen
circumstances. Currently, it is often impractical to recontact individuals
to obtain new or updated consent when circumstances change. If a
judgement is made that the new research is outside of the original
consent and re-consenting is impractical, research ethics committees
and national regulatory bodies are often asked to represent participant
interests. Dynamic consent makes it easy to contact participants and
to provide readily accessible information so that people can make
their own informed decision. However, this does not mean that
dynamic consent should replace the human contact of original
sign-up nor the opportunity for participants to discuss the process
of re-consenting face to face with health professionals.
Conforms to the highest legal standards
Freely given, ‘informed’ consent is a unanimous requirement of
biomedical law, privacy and information legislation across the world.
There are also a number of exemptions from consent for medical
research that exist in law, such as public health surveillance. However,
the exemptions in law are always subject to change as evidenced
by the latest proposals to European Data Protection law.25,38 The
increased ease of participant recontact with a dynamic consent
model offers a flexible and responsive way to deal with changing
legal and ethical requirements. The built-in compliance framework
also ensures adherence to the highest standards in data privacy
protection and risk assessment, going further than the current
standard required by many international legal requirements and
privacy impact assessments.
Fine grained withdrawal
Participants in research have a right to withdraw by requesting that
their samples and data not be made available for research and,
in some cases, that their samples and/or data be destroyed.
However, quite often this withdrawal is ‘all or nothing’. In practice,
there is often no option to limit withdrawal to specific research
that an individual might find objectionable. The choice is
limited to withdrawing from the biobank entirely or giving
broad consent for samples and data to be available for all
research requests that are subsequently approved by the biobank.
Dynamic consent enables choice to be more nuanced and may
mean that research participants will be less likely to withdraw
from a biobank infrastructure than if they have only an ‘all or
nothing’ choice.
Enables better communication
Traditional forms of obtaining consent engage participants at the
outset of the study; however, these are rarely the best mechanisms
to maintain contact with participants or to convey research findings
to those whose material made the research possible. Participants
may or may not want access to scientific reports and publications
but may wonder whatever became of the project to which they
contributed. The dynamic consent interface allows general research
results to be returned to participants according to their preferences,
either as a simple ‘thank you’ for their involvement or by informing
them how their samples and information have been used. Through
this interface, it is possible for participants to link into a wealth of
information that already exists for other purposes, such as lay
descriptions required for grant applications and ethics approval.
It also provides broader possibilities for engagement than just the
information sheet that accompanies the consent form. This can add
value when recruiting previously hard-to-reach audiences, includ-
ing children, service users where English is not their first language
or participants with cognitive, visual or audio impairment.
Indeed, hyperlinks to various alternative forms of presentation
may contribute to overcoming the perennial issue of consent form
length and comprehension.39–41
Improves scientific literacy
By implementing an interface that participants can access in their own
time, there is an additional opportunity for understanding the
information provided to patients and participants and reflection on
its meaning for their particular circumstances. Initial recruitment will
still involve the provision of the information mandated by ethical
review, but participants will be able to access additional information
if, as and when they wish, from brief lay summaries to peer-reviewed
scientific papers. The interface empowers the individual, rather than
researchers, to determine how much, and what sort of, additional
information they access at any point in time. This is likely to lead to a
more realistic understanding of research as an iterative, long-term
process; enhance participant confidence in its transparency and
accountability; and help to develop more appropriate expectations
of what a single piece of research can and cannot achieve. It can
enhance scientific literacy and understanding of the societal benefit of
medical research.
Improves transparency and risk management
Finally, dynamic consent provides greater transparency and account-
ability in the research process as patient samples and data can be
tracked across research studies to remove bias and erroneous
identification. It provides operational control for managing risk
throughout the lifetime of the data holding, providing both an audit
process and early warning system of potential security breaches. It also
provides the means to contact participants for their opinions on
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controversial issues and in doing so safeguards public trust and
ensures accountability.
Box 4 Benefits of Dynamic Consent
 It meets the highest international ethical and legal standards for consent in a
world where data protection laws are in flux.
 It enables participants to keep all of their information in one place, with a
record of consent and research involvement, thus enabling more active
engagement in research.
 Collection of one-off consent for research can often occur at a stressful time
for the person concerned, such as before treatment or surgery; dynamic
consent removes this pressure by allowing participants to return to their
decisions and review their consent preferences in their own time.
 It promotes scientific literacy as participants become more informed about
the research carried out on their samples and information, which encourages
public trust by making research more transparent and accountable.
 For researchers, it provides an easy mechanism to identify individuals who
have consented to being approached and recruited for new studies, to
participate in online surveys or to canvas opinions.
 It can be tailored for specific situations, as a ‘one-stop’ interface to facilitate
better translational research and to coordinate clinical and research activities
co-ordinated around the patient.
CHALLENGES OF IMPLEMENTATION
Implementing a dynamic consent model requires cultural change for
both health-care professionals and individuals. It requires partner-
ships for health that are open, transparent and engaging, and
which understand and value the central role that patients have in
research as the providers of information and biological material. It
also requires development of new policies, standards and ways of
working that can accompany this approach. The system must have the
technical capacity to interface with the systems of the biobanks and
research organisations so it can provide information and feedback to
participants. New processes and technology for testing and monitor-
ing the integrity of dynamic consent technologies must be developed,
to provide operational control for managing risk throughout the
lifetime of the data holding. This requires investment of resources
such as time, money, expertise and, most importantly, a commitment
to such a vision by clinicians and researchers, health-care services,
research institutions and governments. Although there are a number
of challenges for implementing dynamic consent, the opportunities
that the model will provide, using technology to streamline recruit-
ment, consent and re-consent processes and involve more people in
research, will be substantial.
Box 5 Challenges of Implementation
The implementation of dynamic consent requires:
 A change in culture for both health professionals and individuals.
 The development of new kinds of partnerships between researchers and
patients.
 New policies, standards and ways of working that recognise the valuable role
of patients.
 New technologies and processes to provide operational control.
 Time, money, expertise and, most importantly, commitment from clinicians,
researchers, health-care services, research and governments.
CONCLUSIONS
New technologies have improved biomedical research and have led to
significant changes in practice. Dynamic consent is an example of
using IT to meet the ethical and legal requirements for consent and
also providing a means to communicate, engage and recruit indivi-
duals into research.
The initial work for dynamic consent was carried out in the
EnCoRe project (June 2008 to April 2012).42 It was developed in the
context of three biobanks – the Oxford Radcliffe Biobank, the Oxford
Musculoskeletal Biobank, and the Oxford Biobank. Another high-
profile example of the dynamic consent concept is Reg4All.43
Currently, dynamic consent systems are being designed for the
biobanking context. The technical design of the dynamic consent
architecture enables the same interface to be used in clinical or other
research contexts. Consent could be obtained for research uses of
surplus tissue, de novo research projects, organ donation and clinical
trials. These consents could support the flow of new knowledge
between the laboratory and the clinic that is central to translational
research and personalised medicine. Research continues to develop,
and new questions arise. As discussion continues about feedback
relating to incidental findings discovered during medical research
(particularly genomic analysis), the interface would provide a useful
means to broach this issue with participants. It could enable
researchers to gain a better sense of participants’ views on incidental
findings and could ultimately provide the opportunity for partici-
pants to be better informed and to set specific preferences relating to
what feedback they would like, and when and how it is received.
Therefore, while dynamic consent is currently a biobanking project, it
is also an approach or concept that is being applied more broadly, not
only within health but also in other fields.
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